Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives $132.86 Average Target Price from Analysts

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) has received a consensus recommendation of "Buy" from the seven ratings firms that are covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have covered the stock in the last year is $132.86.

Several equities analysts have issued reports on LNTH shares. StockNews.com lowered Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. The Goldman Sachs Group started coverage on Lantheus in a research note on Wednesday, December 18th. They set a "buy" rating and a $143.00 price target on the stock. JMP Securities reiterated a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. Finally, Truist Financial increased their price objective on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th.

Insiders Place Their Bets

In other news, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James H. Thrall sold 1,000 shares of the business's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is owned by insiders.

Remove Ads

Institutional Trading of Lantheus

Several hedge funds have recently modified their holdings of LNTH. Wilmington Savings Fund Society FSB purchased a new position in Lantheus in the third quarter worth $25,000. Kestra Investment Management LLC acquired a new position in shares of Lantheus during the 4th quarter worth $27,000. Summit Securities Group LLC purchased a new position in shares of Lantheus in the 4th quarter valued at about $37,000. UMB Bank n.a. lifted its stake in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after purchasing an additional 134 shares during the period. Finally, RiverPark Advisors LLC purchased a new stake in Lantheus during the third quarter worth about $74,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Stock Up 6.1 %

LNTH traded up $6.11 on Wednesday, reaching $106.34. The company's stock had a trading volume of 1,369,851 shares, compared to its average volume of 921,738. The company has a market capitalization of $7.28 billion, a price-to-earnings ratio of 17.69 and a beta of 0.44. Lantheus has a fifty-two week low of $56.44 and a fifty-two week high of $126.89. The stock has a 50 day moving average of $90.43 and a two-hundred day moving average of $96.80.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. As a group, analysts anticipate that Lantheus will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.